Liver fibrosis staging using T1 mapping on gadoxetic acid-enhanced MRI compared with DW imaging

Y Ding1, S-X Rao1, T Zhu1

  • 1Department of Radiology, Zhongshan Hospital of Fudan University, No. 180, Fenglin Road, Xuhui District, Shanghai, 200032, China.

Clinical Radiology
|July 13, 2015
PubMed
Abstract

Insights

Hepatobiliary phase T1 mapping on gadoxetic acid-enhanced MRI shows promise for staging liver fibrosis. This method demonstrated higher accuracy than diffusion-weighted imaging's apparent diffusion coefficient (ADC) in assessing fibrosis severity.

Area of Science:

  • Radiology
  • Hepatology
  • Medical Imaging

Background:

  • Liver fibrosis staging is crucial for patient management.
  • Non-invasive biomarkers are needed to supplement or replace liver biopsy.
  • Gadoxetic acid-enhanced MRI offers unique imaging capabilities.

Purpose of the Study:

  • To assess the utility of T1 mapping in gadoxetic acid-enhanced MRI for liver fibrosis staging.
  • To compare the diagnostic performance of T1 mapping with diffusion-weighted imaging (DWI).

Main Methods:

  • Retrospective analysis of 145 patients with histopathologically confirmed liver fibrosis stage (S) and necro-inflammatory grade (G).
  • Measurement of liver T1 relaxation time and apparent diffusion coefficient (ADC).
  • Calculation of T1 relaxation time reduction rate (Δ%) and comparison with S/G scores.

Main Results:

  • Hepatobiliary phase (HBP) T1 relaxation time and Δ% correlated significantly with fibrosis stage (S) and grade (G).
  • ADC values correlated significantly with S but not G.
  • HBP T1 relaxation time showed superior accuracy (AUC 0.82 for S≥3) compared to ADC (AUC 0.71 for S≥3) for fibrosis staging.

Conclusions:

  • Hepatobiliary phase T1 relaxation time measurement is a potential non-invasive biomarker for liver fibrosis staging.
  • T1 mapping on gadoxetic acid-enhanced MRI is more accurate than ADC for assessing liver fibrosis severity.